{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:29:51Z","timestamp":1784204991682,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00277-023-05472-3","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T02:01:37Z","timestamp":1695693697000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retrospective cohort evaluation of non-HIV Castleman disease from a single academic center in Beijing, China"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5014-3347","authenticated-orcid":false,"given":"Meiyu","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"issue":"84","key":"5472_CR1","first-page":"1","volume":"7","author":"A Carbone","year":"2021","unstructured":"Carbone A, Borok M, Damania B et al (2021) Castleman disease. Blood. 7(84):1\u201318","journal-title":"Blood."},{"key":"5472_CR2","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3109\/10428194.2014.953145","volume":"56","author":"N Munshi","year":"2015","unstructured":"Munshi N, Mehra M, van de Velde H et al (2015) Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 56:1252\u20131260","journal-title":"Leuk Lymphoma"},{"key":"5472_CR3","doi-asserted-by":"publisher","first-page":"23831","DOI":"10.1038\/srep23831","volume":"6","author":"Z Lu","year":"2016","unstructured":"Lu Z, Li Z, Cao X et al (2016) Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman\u2019s disease: renal function is an important prognostic factor[J]. Sci Rep 6:23831","journal-title":"Sci Rep"},{"issue":"6","key":"5472_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/bjh.13378","volume":"169","author":"Y Dong","year":"2015","unstructured":"Dong Y, Wang M, Nong L et al (2015) Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol 169(6):834\u2013842","journal-title":"Br J Haematol"},{"issue":"3","key":"5472_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","volume":"31","author":"H Umehara","year":"2021","unstructured":"Umehara H, Okazaki K, Kawa S et al (2021) Research program for intractable disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31(3):529\u2013533","journal-title":"Mod Rheumatol"},{"issue":"16","key":"5472_CR6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","volume":"135","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC (2020) Overview of Castleman disease. Blood. 135(16):1353\u20131364","journal-title":"Blood."},{"issue":"2","key":"5472_CR7","first-page":"2407","volume":"15","author":"JP Jiang","year":"2018","unstructured":"Jiang JP, Shen XF, Du JF et al (2018) A retrospective study of 34 patients with unicentric and multicentric Castleman\u2019s disease: experience from a single institution. Oncol Lett 15(2):2407\u20132412","journal-title":"Oncol Lett"},{"key":"5472_CR8","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","volume":"129","author":"DC Fajgenbaum","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A et al (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 129:1646\u20131657","journal-title":"Blood."},{"issue":"20","key":"5472_CR9","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A et al (2018) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 132(20):2115\u20132124","journal-title":"Blood."},{"issue":"23","key":"5472_CR10","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1182\/bloodadvances.2020003334","volume":"4","author":"F van Rhee","year":"2020","unstructured":"van Rhee F, Oksenhendler E, Srkalovic G et al (2020) International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv 4(23):6039\u20136050","journal-title":"Blood Adv"},{"issue":"9","key":"5472_CR11","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-018-3347-0","volume":"97","author":"Y Dong","year":"2018","unstructured":"Dong Y, Zhang L, Nong L et al (2018) Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Ann Hematol 97(9):1641\u20131647","journal-title":"Ann Hematol"},{"issue":"8","key":"5472_CR12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1080\/10428190903060095","volume":"50","author":"Y Dong","year":"2009","unstructured":"Dong Y, Na J, Lv J et al (2009) Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center. Leuk Lymphoma 50(8):1308\u20131317","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"5472_CR13","first-page":"529","volume":"42","author":"Hematology Committee of Chinese Medical Association; Hematological Oncology Committee of China Anti-Cancer Association; China Castleman Disease Network (CCDN)","year":"2021","unstructured":"Hematology Committee of Chinese Medical Association; Hematological Oncology Committee of China Anti-Cancer Association; China Castleman Disease Network (CCDN) (2021) The consensus of the diagnosis and treatment of Castleman disease in China (2021). Zhonghua Xue Ye Xue Za Zhi 42(7):529\u2013534","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"5472_CR14","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/ajh.26292","volume":"96","author":"N Yoshito","year":"2021","unstructured":"Yoshito N, Fajgenbaum David C, Pierson Sheila K et al (2021) Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol 96:1241\u20131252","journal-title":"Am J Hematol"},{"issue":"5","key":"5472_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.32074\/1591-951X-351","volume":"113","author":"T Zhou","year":"2021","unstructured":"Zhou T, Wang HW, Pittaluga S et al (2021) Multicentric Castleman disease and the evolution of the concept. Pathologica. 113(5):339\u2013354","journal-title":"Pathologica."},{"issue":"5","key":"5472_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.32074\/1591-951X-331","volume":"113","author":"F Facchetti","year":"2021","unstructured":"Facchetti F, Simbeni M, Lorenzi L (2021) Follicular dendritic cell sarcoma. Pathologica. 113(5):316\u2013329","journal-title":"Pathologica."},{"issue":"23","key":"5472_CR17","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.2169\/internalmedicine.5046-20","volume":"59","author":"K Shiroshita","year":"2020","unstructured":"Shiroshita K, Kikuchi T, Okayama M et al (2020) Interleukin-6-producing intravascular large B-cell lymphoma with lymphadenopathy mimicking the histology of multicentric Castleman disease. Intern Med 59(23):3061\u20133065","journal-title":"Intern Med"},{"key":"5472_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.humpath.2017.08.024","volume":"68","author":"S Pina-Oviedo","year":"2017","unstructured":"Pina-Oviedo S, Miranda RN, Lin P et al (2017) Follicular lymphoma with hyaline-vascular Castleman-like features: analysis of 6 cases and review of the literature. Hum Pathol 68:136\u2013146","journal-title":"Hum Pathol"},{"issue":"12","key":"5472_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/jcp.2010.082958","volume":"63","author":"Y Sato","year":"2010","unstructured":"Sato Y, Kojima M, Takata K et al (2010) Multicentric Castleman\u2019s disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol 63(12):1084\u20131089","journal-title":"J Clin Pathol"},{"issue":"1","key":"5472_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/pin.13185","volume":"72","author":"A Nishikori","year":"2021","unstructured":"Nishikori A, Nishimura MF, Nishimura Y et al (2021) Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease. Pathol Int 72(1):43\u201352","journal-title":"Pathol Int"},{"issue":"6","key":"5472_CR21","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.18632\/oncotarget.24068","volume":"9","author":"K Otani","year":"2018","unstructured":"Otani K, Inoue D, Fujikura K et al (2018) Idiopathic multicentric Castleman\u2019s disease: a clinicopathologic study in comparison with IgG4-related disease. Oncotarget. 9(6):6691\u20136706","journal-title":"Oncotarget."},{"issue":"2","key":"5472_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ajh.10022","volume":"69","author":"C Larroche","year":"2002","unstructured":"Larroche C, Cacoub P, Soulier J et al (2002) Castleman\u2019s disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol 69(2):119\u2013126","journal-title":"Am J Hematol"},{"issue":"3","key":"5472_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/ajcp\/aqaa053","volume":"154","author":"L Wang","year":"2020","unstructured":"Wang L, Nong L, Li F et al (2020) Predominant stroma-rich feature in hyaline vascular variant of Castleman disease is associated with paraneoplastic pemphigus: a 20-year retrospective study of 123 Chinese patients with Castleman disease. Am J Clin Pathol 154(3):403\u2013413","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"5472_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/medicina57101080","volume":"57","author":"AM Malik","year":"2021","unstructured":"Malik AM, Tupchong S, Huang S et al (2021) An updated review of pemphigus diseases. Medicina. 57(10):1080","journal-title":"Medicina."},{"issue":"9","key":"5472_CR25","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/cup.14004","volume":"48","author":"SA Svoboda","year":"2021","unstructured":"Svoboda SA, Huang S, Liu X et al (2021) Paraneoplastic pemphigus: revised diagnostic criteria based on literature analysis. J Cutan Pathol 48(9):1133\u20131138","journal-title":"J Cutan Pathol"},{"issue":"9","key":"5472_CR26","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","volume":"15","author":"F Van Rhee","year":"2014","unstructured":"Van Rhee F, Wong RS, Munshi N et al (2014) Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15(9):966\u2013974","journal-title":"Lancet Oncol"},{"issue":"16","key":"5472_CR27","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1182\/bloodadvances.2022007112","volume":"6","author":"F van Rhee","year":"2022","unstructured":"van Rhee F, Rosenthal A et al (2022) Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv 6(16):4773\u20134781","journal-title":"Blood Adv"},{"issue":"16","key":"5472_CR28","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2018-11-884577","volume":"133","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhao AL, Duan MH et al (2019) Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood. 133(16):1720\u20131728","journal-title":"Blood."},{"issue":"3","key":"5472_CR29","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/10428194.2021.1999437","volume":"63","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhang M, Cao X et al (2022) A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed\/refractory iMCD. Leuk Lymphoma 63(3):618\u2013626","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"5472_CR30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3109\/10428194.2011.574759","volume":"52","author":"D Shin","year":"2011","unstructured":"Shin D, Jeon YK, Hong YS et al (2011) Clinical dissection of multicentric Castleman disease. Leuk Lymphoma 52(8):1517\u20131522","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"5472_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.17116\/terarkh201587764-71","volume":"87","author":"AL Melikyan","year":"2015","unstructured":"Melikyan AL, Egorova EK, Kovrigina AM et al (2015) Clinical and morphological features of different types of Castleman\u2019s disease. Ter Arkh 87(7):64\u201371","journal-title":"Ter Arkh"},{"issue":"11","key":"5472_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.23291","volume":"87","author":"A Dispenzieri","year":"2012","unstructured":"Dispenzieri A, Armitage JO, Loe MJ et al (2012) The clinical spectrum of Castleman\u2019s disease. Am J Hematol 87(11):997\u20131002","journal-title":"Am J Hematol"},{"issue":"4","key":"5472_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5045\/br.2014.49.4.253","volume":"49","author":"S Seo","year":"2014","unstructured":"Seo S, Yoo C, Yoon DH et al (2014) Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman\u2019s disease: a single medical center experience. Blood Res 49(4):253\u2013258","journal-title":"Blood Res"},{"key":"5472_CR34","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1748759\/v1","volume-title":"A real-world study on a large retrospective cohort of Castleman disease from a single center","author":"M Guo","year":"2022","unstructured":"Guo M, Lin N, Wang M et al (2022, PREPRINT (Version 1) available at Research Square) A real-world study on a large retrospective cohort of Castleman disease from a single center. https:\/\/doi.org\/10.21203\/rs.3.rs-1748759\/v1"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05472-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05472-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05472-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:03:20Z","timestamp":1704218600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05472-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5472"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05472-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"3 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}